ArticleJACC. Case reports2025
Treatment With Inclisiran During Peritoneal Dialysis.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox.Cardiovascular drugs and therapy · 2026Review
- Inclisiran in Dyslipidemia with High Residual Platelet Reactivity.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInclisiran is a small interfering RNA that prevents PCSK9 (proprotein convertase subtilisin/kexin type 9) synthesis, lowering low-density lipoprotein cholesterol. In ORION trials, efficacy and safety outcomes of inclisiran were similar among different renal impairment degrees, but no data are available in peritoneal dialysis (PD). CASE SUMMARY: We present the case of a 47-year-old woman with severe and recurrent cardiovascular disease and end-stage renal disease on PD. Following inclisiran injection, low-density lipoprotein cholesterol levels significantly decreased by 56.2% at 3 months. Reductions in apolipoprotein B, lipoprotein(a), and PCSK9 concentration were observed. No side effects were reported. DISCUSSION: This report suggests, for the first time, that inclisiran may represent a potential treatment option for lipid control in patients undergoing PD, with results comparable to those reported in clinical trials and a good tolerability profile. TAKE-HOME MESSAGE: Inclisiran is a potential lipid-lowering therapy in patients on peritoneal dialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.